JP7796531B2 - 抗ヒトｃｄ４５ｒｃ抗体及びその使用 - Google Patents

抗ヒトｃｄ４５ｒｃ抗体及びその使用

Info

Publication number
JP7796531B2
JP7796531B2 JP2021516406A JP2021516406A JP7796531B2 JP 7796531 B2 JP7796531 B2 JP 7796531B2 JP 2021516406 A JP2021516406 A JP 2021516406A JP 2021516406 A JP2021516406 A JP 2021516406A JP 7796531 B2 JP7796531 B2 JP 7796531B2
Authority
JP
Japan
Prior art keywords
seq
antibody
binding fragment
lcvr
hcvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021516406A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020058495A5 (https=
JP2022502024A (ja
JP2022502024A5 (https=
Inventor
ギヨンヌ，キャロル
アネゴン，イグナシオ
Original Assignee
インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル）
ナント ユニベルシテ
センター ホスピタリア ユニバーシタイア デ ナント
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル）, ナント ユニベルシテ, センター ホスピタリア ユニバーシタイア デ ナント filed Critical インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル）
Publication of JP2022502024A publication Critical patent/JP2022502024A/ja
Publication of JPWO2020058495A5 publication Critical patent/JPWO2020058495A5/ja
Publication of JP2022502024A5 publication Critical patent/JP2022502024A5/ja
Priority to JP2025124669A priority Critical patent/JP2025164963A/ja
Application granted granted Critical
Publication of JP7796531B2 publication Critical patent/JP7796531B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021516406A 2018-09-21 2019-09-20 抗ヒトｃｄ４５ｒｃ抗体及びその使用 Active JP7796531B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025124669A JP2025164963A (ja) 2018-09-21 2025-07-25 抗ヒトｃｄ４５ｒｃ抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306230.6 2018-09-21
EP18306230.6A EP3626265A1 (en) 2018-09-21 2018-09-21 Anti-human cd45rc antibodies and uses thereof
PCT/EP2019/075374 WO2020058495A1 (en) 2018-09-21 2019-09-20 Anti-human cd45rc antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025124669A Division JP2025164963A (ja) 2018-09-21 2025-07-25 抗ヒトｃｄ４５ｒｃ抗体及びその使用

Publications (4)

Publication Number Publication Date
JP2022502024A JP2022502024A (ja) 2022-01-11
JPWO2020058495A5 JPWO2020058495A5 (https=) 2022-09-29
JP2022502024A5 JP2022502024A5 (https=) 2022-09-29
JP7796531B2 true JP7796531B2 (ja) 2026-01-09

Family

ID=63713787

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021516406A Active JP7796531B2 (ja) 2018-09-21 2019-09-20 抗ヒトｃｄ４５ｒｃ抗体及びその使用
JP2025124669A Pending JP2025164963A (ja) 2018-09-21 2025-07-25 抗ヒトｃｄ４５ｒｃ抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025124669A Pending JP2025164963A (ja) 2018-09-21 2025-07-25 抗ヒトｃｄ４５ｒｃ抗体及びその使用

Country Status (13)

Country Link
US (2) US12168694B2 (https=)
EP (2) EP3626265A1 (https=)
JP (2) JP7796531B2 (https=)
KR (1) KR20210070303A (https=)
CN (1) CN113164595A (https=)
AU (1) AU2019343746C1 (https=)
BR (1) BR112021005276A2 (https=)
CA (1) CA3113562A1 (https=)
IL (1) IL281608B2 (https=)
MX (1) MX2021003281A (https=)
NZ (1) NZ774030A (https=)
SG (1) SG11202102659RA (https=)
WO (1) WO2020058495A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025164963A (ja) * 2018-09-21 2025-10-31 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 抗ヒトｃｄ４５ｒｃ抗体及びその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3172120A1 (en) * 2020-03-20 2021-09-23 Inserm (Institut De La Sante Et De La Recherche Medicale) Chimeric antigen receptor specific for human cd45rc and uses thereof
WO2023041717A1 (en) 2021-09-16 2023-03-23 Aboleris Pharma Anti-human cd45rc binding domains and uses thereof
WO2023118608A1 (en) 2021-12-23 2023-06-29 Universität Basel Discernible cell surface protein variants of cd45 for use in cell therapy
JP2026500540A (ja) 2022-12-23 2026-01-07 シメイオ セラピューティクス アーゲー Ｃｄ４５を標的とする抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017527541A (ja) 2014-08-01 2017-09-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 薬物としての使用のための抗ｃｄ４５ｒｃ抗体

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
AU2005218642B2 (en) 2004-03-02 2011-04-28 Seagen Inc. Partially loaded antibodies and methods of their conjugation
WO2006132670A2 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
EP1898529A1 (en) 2005-06-28 2008-03-12 Pioneer Corporation Broadcast receiving apparatus, interference detecting apparatus and interference detecting method
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
KR20080068089A (ko) 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
DK2602323T3 (en) 2007-06-01 2018-04-16 Open Monoclonal Tech Inc Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
FR3003171B1 (fr) 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) * 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017527541A (ja) 2014-08-01 2017-09-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 薬物としての使用のための抗ｃｄ４５ｒｃ抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
柴田 賢，ＣＤ４５抗原を認識する新たな抗体ＬＨ４９２６の特性，大阪大学医学雑誌，1996年01月25日，48(1)，pp. 1-13，ISSN: 0369-710X

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025164963A (ja) * 2018-09-21 2025-10-31 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 抗ヒトｃｄ４５ｒｃ抗体及びその使用

Also Published As

Publication number Publication date
JP2025164963A (ja) 2025-10-31
EP3852802A1 (en) 2021-07-28
BR112021005276A2 (pt) 2021-07-13
KR20210070303A (ko) 2021-06-14
JP2022502024A (ja) 2022-01-11
US12168694B2 (en) 2024-12-17
CN113164595A (zh) 2021-07-23
IL281608B1 (en) 2025-12-01
AU2019343746B2 (en) 2025-12-04
WO2020058495A1 (en) 2020-03-26
AU2019343746C1 (en) 2026-04-02
MX2021003281A (es) 2021-08-11
AU2019343746A1 (en) 2021-04-15
SG11202102659RA (en) 2021-04-29
NZ774030A (en) 2026-03-27
US20220033500A1 (en) 2022-02-03
US20250122300A1 (en) 2025-04-17
CA3113562A1 (en) 2020-03-26
IL281608A (en) 2021-05-31
EP3626265A1 (en) 2020-03-25
IL281608B2 (en) 2026-04-01

Similar Documents

Publication Publication Date Title
JP7796531B2 (ja) 抗ヒトｃｄ４５ｒｃ抗体及びその使用
TWI674274B (zh) 抗體－飛諾莫接合物
JP2023078167A (ja) ＳＩＲＰα結合タンパク質及びその使用方法
JP6012473B2 (ja) 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
JP7796034B2 (ja) ヒトｃｄ４５ｒｃに特異的なキメラ抗原受容体およびその使用
JP2024503724A (ja) 免疫調節抗体およびその使用
US20250313631A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
WO2019075523A1 (en) PROCESS
BR112021014574A2 (pt) Competidores cd31 e usos dos mesmos
EP4393949A1 (en) Pharmaceutical composition containing fusion protein
RU2826421C2 (ru) Выделенное антитело к CD45RC человека, нуклеиновая кислота, вектор экспрессии, клетка, фармацевтическая композиция, их применение, in vitro способ обнаружения hCD45RC
CN118591386A (zh) 抗突变体钙网蛋白(calr)抗体及其用途
JP2025539142A (ja) ヒト化抗ａｇｒ２抗体
CN114555120A (zh) 用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240424

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20240610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250307

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251223

R150 Certificate of patent or registration of utility model

Ref document number: 7796531

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150